本研究旨在比較亞洲停經後ER(+)/HER2(-)晚期乳癌女性接受letrozole聯合Palbociclib治療與letrozole聯合安慰劑治療後的臨床獲益，該等患者未曾因晚期/轉移性疾病接受過全身性抗癌治療。
適應症：Breast Neoplasms
收案條件
納入條件
- Adult Asian women with locoregionally recurrent or metastatic disease not amenable to curative therapy
- Confirmed diagnosis of ER positive breast cancer
- No prior systemic anti-cancer therapy for advanced ER+ disease
- Postmenopausal women
- Measurable disease as per Response Evaluation Criterion in Solid Tumors \[RECIST\] or bone-only disease
- Eastern Cooperative Oncology Group \[ECOG\] 0-1
- Adequate organ and marrow function
- Patient must agree to provide tumor tissue
排除條件
- Confirmed diagnosis of HER2 positive disease
- Patients with advanced, symptomatic, visceral spread that are at risk of life threatening complication in the short term
- Known uncontrolled or symptomatic CNS metastases
- Prior neoadjuvant or adjuvant treatment with a non steroidal aromatase inhibitor (ie, anastrozole or letrozole) with disease recurrence while on or within 12 months of completing treatment
- Prior treatment with any CDK 4/6 inhibitor
收案條件維持 ClinicalTrials.gov 原始英文登錄資料，實際收案資格以研究團隊的正式評估與受試者同意書為準。資料來源：ClinicalTrials.gov，每兩週自動更新，最後同步：2026年10月8日。